Further, inhibiting both TGFβ2 and TGFβ3 while sparing TGFβ1 could alleviate lung fibrosis while avoiding toxicity concerns associated with pan-TGFβ blockade. This evidence concerns the gene TGFB2 and pulmonary fibrosis.